Table 3.
Clinical outcomes of all patients with and without diabetes, and of all patients with and without diabetes stratified according to medical therapy or successful CTO-PCI
| Total population | Non-diabetes | Diabetes | P value |
|---|---|---|---|
| (n = 1260) | (n = 755) | ||
| Cardiac death | 59 (4.7) | 38 (5.0) | |
| Adjusted HR (95% CI) | 1 | 1.13 (0.73–1.75) | 0.597 |
| MI | 86 (6.8) | 69 (9.1) | |
| Adjusted HR (95% CI) | 1 | 1.38 (0.98–1.92) | 0.058 |
| TVR | 155 (12.3) | 113 (15.0) | |
| Adjusted HR (95% CI) | 1 | 1.41 (1.10–1.81) | 0.006 |
| MACE | 257 (20.4) | 192 (25.4) | |
| Adjusted HR (95% CI) | 1 | 1.32 (1.09–1.61) | 0.005 |
| Patients with diabetes | Medical therapy | Successful PCI | P value |
|---|---|---|---|
| (n = 506) | (n = 249) | ||
| Cardiac death | 33 (6.5) | 5 (2.0) | |
| Adjusted HR (95% CI) | 1 | 0.29 (0.10–0.80) | 0.017 |
| MI | 50 (9.9) | 19 (7.6) | |
| Adjusted HR (95% CI) | 1 | 0.75 (0.44–1.30) | 0.305 |
| TVR | 79 (15.6) | 34 (13.7) | |
| Adjusted HR (95% CI) | 1 | 0.76 (0.50–1.17) | 0.212 |
| MACE | 146 (28.9) | 46 (18.5) | |
| Adjusted HR (95% CI) | 1 | 0.61 (0.42–0.87) | 0.006 |
| Patients with diabetes | Medical therapy | Successful PCI | P value |
|---|---|---|---|
| (n = 791) | (n = 469) | ||
| Cardiac death | 41 (5.2) | 18 (3.8) | |
| Adjusted HR (95% CI) | 1 | 0.94 (0.51–1.70) | 0.825 |
| MI | 56 (7.1) | 30 (6.4) | |
| Adjusted HR (95% CI) | 1 | 1.01 (0.62–1.65) | 0.959 |
| TVR | 109 (13.8) | 46 (9.8) | |
| Adjusted HR (95% CI) | 1 | 0.85 (0.59–1.22) | 0.389 |
| MACE | 180 (22.8) | 77 (16.4) | |
| Adjusted HR (95% CI) | 1 | 0.85 (0.64–1.15) | 0.294 |
Values are presented as n (%)
CI confidence interval(s), HR hazard ratio, MACE major adverse cardiovascular events, MI myocardial infarction, PCI percutaneous coronary intervention, TVR target-vessel revascularization